0001372514-24-000057.txt : 20240607 0001372514-24-000057.hdr.sgml : 20240607 20240607070221 ACCESSION NUMBER: 0001372514-24-000057 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240606 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 241027259 BUSINESS ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: 781-788-8869 MAIL ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 8-K 1 kprx-20240606.htm 8-K kprx-20240606
0001372514false12/3100013725142024-06-062024-06-0600013725142024-01-012024-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 6, 2024
KIORA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-3667298-0443284
(Commission File Number)(IRS Employer Identification No.)

332 Encinitas Blvd.
Suite 102
Encinitas, CA 92024
(858) 224-9600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading Symbol(s)Name of each exchange on which registered:
Common Stock, $0.01 par valueKPRXNASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 3.03.    Material Modification to Rights of Security Holders.

The information set forth in Item 5.03 is incorporated herein by reference.

Item 5.03.    Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 6, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”), which was approved by the Company’s stockholders at the Company’s 2024 Annual Meeting of Stockholders held on May 1, 2024 and by the Company’s Board of Directors.

The Certificate of Amendment effects a 1-for-9 reverse stock split of the Company’s common stock, par value $0.01 per share (the “Common Stock”), in which each nine (9) shares of Common Stock issued and outstanding as of 12:01 a.m. Eastern Time on June 11, 2024 (the effective time of the reverse stock split) will be combined and converted into one share of Common Stock. While the reverse stock split will decrease the number of outstanding shares of Common Stock, it will not change the total number of shares of Common Stock authorized for issuance by the Company, nor will it change the par value of the Common Stock. The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market.

No fractional shares of Common Stock will be issued in connection with the reverse stock split. Instead, the Company will pay cash to any stockholder holding fractional shares as a result of the reverse stock split equal to such fraction multiplied by the closing price per share of Common Stock on The Nasdaq Capital Market as of June 10, 2024, as adjusted to reflect the reverse stock split.

This summary of the Certificate of Amendment is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and incorporated by reference herein.

The Company expects that the reverse stock split-adjusted shares of its Common Stock will begin trading on The Nasdaq Capital Market at the open of the market on June 11, 2024 under the new CUSIP number 49721T 507. No change will be made to the trading symbol for the Common Stock, “KPRX”, in connection with the reverse stock split.

In connection with the reverse stock split, proportional adjustments will be made to (i) the number of shares of Common Stock underlying the Company’s outstanding stock options and warrants, (ii) the exercise price or conversion price (as applicable) of the Company’s outstanding stock options and warrants, and (iii) the number of shares reserved for issuance under the Company’s equity incentive plan.

Item 8.01.    Other Items.
Immediately prior to the reverse stock split, there were 26,735,116 shares of Common Stock outstanding. Immediately following the reverse stock split, there will be approximately 2,970,568 shares of Common Stock outstanding, subject to adjustment to reflect the elimination of fractional shares. Immediately prior to the reverse stock split there were warrants to purchase 67,136,173 shares of Common Stock outstanding, inclusive of pre-funded warrants to purchase 11,354,237 shares of Common Stock and reflecting a decrease of 3,427,479 shares underlying Class D warrants that expired on June 6, 2024. Immediately following the reverse stock split, there will be warrants to purchase approximately 7,459,575 shares of Common Stock outstanding, inclusive of pre-funded warrants to purchase approximately 1,261,582 shares of Common Stock. Immediately prior to the reverse stock split, there were 100,056,883 shares of Common Stock outstanding on a fully diluted basis. Immediately following the reverse stock split, there will be approximately 11,117,431 shares of Common Stock outstanding on a fully diluted basis.


Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 
Number		Title
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KIORA PHARMACEUTICALS, INC.
By:/s/ Melissa Tosca
Melissa Tosca
Executive Vice President of Finance
(Principal financial and accounting officer)
Date: June 7, 2024

 EX-3.1 2 a31certificateofamendment.htm EX-3.1 Document

CERTIFICATE OF AMENDMENT
TO THE RESTATED CERTIFICATE OF INCORPORATION  

Pursuant to Section 242 of the General Corporation Law of the State of Delaware

Kiora Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows:

FIRST: The name of the Corporation is Kiora Pharmaceuticals, Inc.

SECOND: The date on which the Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of the State of Delaware is December 28, 2004, and was amended and restated by the Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on February 18, 2015, as amended by (i) a Certificate of Amendment to the Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on July 10, 2018 and effective as of that date, (ii) a Certificate of Amendment to the Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on August 28, 2019 and effective as of August 30, 2019, (iii) a Certificate of Amendment to Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on June 25, 2020 and effective as of that date, (iv) a Certificate of Ownership and Merger Merging Kiora Pharmaceuticals, Inc. with and into EyeGate Pharmaceuticals, Inc., which included a change of the name of EyeGate Pharmaceuticals, Inc. to Kiora Pharmaceuticals, Inc., as filed with the Secretary of State of the State of Delaware on November 5, 2021 and effective as of November 8, 2021, (v) a Certificate of Amendment to Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on September 23, 2022, and (vi) a Certificate of Amendment to Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on May 1, 2024 (as amended and restated, the “Certificate”).

THIRD: The Corporation hereby amends the Certificate as follows:

ARTICLE IV, Subsection (A) of the Certificate is hereby amended by adding the following paragraph at the end of such section:

“Upon the effectiveness of this Certificate of Amendment to the Restated Certificate of Incorporation of the Corporation, each nine (9) shares of Common Stock issued and outstanding at such time shall, automatically and without any further action on the part of the Corporation or the holder thereof, be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock (the “Reverse Stock Split”). The par value of the Common Stock following the Reverse Stock Split shall remain $0.01 per share. No fractional shares shall be issued, and, in lieu thereof, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock, as determined by the Board of Directors. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (an “Old Certificate”) shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.”

FOURTH: This Certificate of Amendment has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

FIFTH: The Certificate of Amendment shall be effective on June 11, 2024 at 12:01 am ET.

IN WITNESS WHEREOF, Kiora Pharmaceuticals, Inc. has caused this Certificate of Amendment to be signed by its president and chief executive officer this 6th day of June, 2024.


KIORA PHARMACEUTICALS, INC.

By: /s/ Brian M. Strem, Ph.D.
Name:  Brian M. Strem, Ph.D.
Title: President and Chief Executive Officer

 EX-101.SCH 3 kprx-20240606.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 kprx-20240606_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 kprx-20240606_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
 12 Months Ended
Jun. 06, 2024
Dec. 31, 2024
Cover [Abstract]    
Document Type 8-K  
Document Period End Date Jun. 06, 2024  
Entity Registrant Name KIORA PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 98-0443284  
Entity File Number 001-36672  
Entity Address, Address Line One 332 Encinitas Blvd.  
Entity Address, Address Line Two Suite 102  
Entity Address, City or Town Encinitas  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92024  
City Area Code 858  
Local Phone Number 224-9600  
Written Communications false  
Soliciting Material false  
Pre-commencement Tender Offer false  
Pre-commencement Issuer Tender Offer false  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol KPRX  
Security Exchange Name NASDAQ  
Entity Emerging Growth Company false  
Entity Central Index Key 0001372514  
Amendment Flag false  
Current Fiscal Year End Date   --12-31
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $DXQU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !).,=8HOK65NX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)^G**J';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M $DXQUC<^KE_+04 $T: 8 >&PO=V]R:W-H965T&UL MM9EM<^(V%(7_BH9V.NU,")9,"-DFS!B'=&G>*+#=ODP_"%N )K9%91F2?U_) M$#O9E2^LIWP!V_@<]%A7\K%\N1'R*5TRIM!S'"7I56.IU.I#JY4&2Q;3]%2L M6*)_F0L94Z5WY:*5KB2C82Z*HQ9QG$XKICQI]"[S8R/9NQ29BGC"1A*E61Q3 M^=)GD=A<-7#C]<"8+Y;*'&CU+E=TP29,?5J-I-YK%2XACUF297#0]_ M\,FY$>1G_,[9)GVSC0S*3(@GLS,,KQJ.:1&+6*",!=5?:^:S*#).NAW_[DP; MQ7\:X=OM5_>;'%[#S&C*?!%]YJ%:7C6Z#12R.G+BME(87FW>6LC D4UB\+O/"K*Q,T* F:*< [8#-&R2*JQWKRNH'N]'GH,;&6ZQY+UR5Z<@MXPA5-43]: MA];Q"KO4!7\3,G!]\.E&6,%ARTG&]7C'CK6;86U=7%+BDF_"]GIJF8I-8 M4??9[?K7B@IJZZ*6,0F#P>0KU&(:'DFQYDE@KVG8T_>LH,=(2+B,2!@..5^" MCD2J:(3^XJO*.\T>QXNJ/ 'KZI*6T0G#B2>O5D\_$U:#P0;=LZX5ZQ@Y"9=! M"<,)YTX$NK]&2Y% ]Y8])H2TFQ<=Q['R'2,4X3(583BY?)9<*9;H3HOC+-EE M!-N4T=]C-*=1:NMV'];5!2QS$(9CRT1$/."*)PMTKR<9R6EDI8-=JNF.$7QP MF7PP'%M&DC4#W75,SYG;9S&FGZPE>IS/*RH5]JOF/$8&(F4&(G!@^8ISF*:9 MYMR'N\>V$A?6U<4MDP^!8\J4*YUEQ1QA\N/L)S1A0:;'Z8N5$'8RXUJ'_HD2 MP=,)^MXY=3!:48G6-,KLY,<(0:0,001.+5-)0S-6)R_Q3%A'ZAZ#V]'X#RO7 M,1(/*1,/@=/):Q>BP7.PI,F"53YQ[S%Z\";7WF]6PF-$'5)&'7)0U!G$3"Y, M#_ZB'=32W%A6-+&7+FQ8/3B/D71(F70('%1VH+Z>AJ3.!D,] SVC6V9'A*T< M_=CIGI,S;%^[/$;T(67T(7!J\?1$&^:3[4U$%U8ZV*"Z X^1>4B9>0@<5?Q, MRAR+IR;<_QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK= MT*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G M7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y M*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W M7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M, MDP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1! MBEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_ MD/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[ M:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y M_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J6 M9? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE M 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ 23C' M6)>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5 MN %(MB6/:(7->=I3W; M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II% MR=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/4 M6PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO40 M9.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3 MF:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ 23C' M6"0>FZ*M ^ $ !H !X;"]?+7_OR4Z? M:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-D MGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R M&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( M $DXQUAED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[# M,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7 MK-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ M*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@ M9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WC MEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2F MKW@ALO7L^T%.6X.^D&PO M=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( $DXQUC<^KE_+04 $T: 8 M " @0T( !X;"]W;W)K&PO M&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !).,=899!YDAD! #/ M P $P @ %Z$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" #$% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 2 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.eyegatepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports kprx-20240606.htm kprx-20240606.xsd kprx-20240606_lab.xml kprx-20240606_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "kprx-20240606.htm": { "nsprefix": "kprx", "nsuri": "http://www.eyegatepharma.com/20240606", "dts": { "inline": { "local": [ "kprx-20240606.htm" ] }, "schema": { "local": [ "kprx-20240606.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "kprx-20240606_lab.xml" ] }, "presentationLink": { "local": [ "kprx-20240606_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 2, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.eyegatepharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kprx-20240606.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kprx-20240606.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001372514-24-000057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001372514-24-000057-xbrl.zip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end XML 17 kprx-20240606_htm.xml IDEA: XBRL DOCUMENT 0001372514 2024-06-06 2024-06-06 0001372514 2024-01-01 2024-12-31 0001372514 false --12-31 8-K 2024-06-06 KIORA PHARMACEUTICALS, INC. DE 001-36672 98-0443284 332 Encinitas Blvd. Suite 102 Encinitas CA 92024 858 224-9600 false false false false Common Stock, $0.01 par value KPRX NASDAQ false